Resource Summary Report

Generated by RRID on Sep 1, 2026

NCI-H23

RRID:CVCL_1547
Type: Cell Line

Proper Citation

RRID:CVCL_1547

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1547

Proper Citation: RRID:CVCL_1547

Description: Cell line NCI-H23 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung adenocarcinoma

Defining Citation: PMID:1311061, PMID:1565469, PMID:1845952, PMID:2041050, PMID:2473086, PMID:3335022, PMID:3940644, PMID:6148444, PMID:6270685, PMID:6272398, PMID:7718330, PMID:8626706, PMID:8806092, PMID:9331090, PMID:10358721, PMID:10536175, PMID:10700174, PMID:11005564, PMID:11030152, PMID:12820372, PMID:15471562, PMID:15748285, PMID:15900046, PMID:17088437, PMID:19153074, PMID:19372543, PMID:19472407, PMID:20164919, PMID:20215515, PMID:20557307, PMID:22068913, PMID:22336246, PMID:22347499, PMID:22384151, PMID:22460905, PMID:22628656, PMID:22961666, PMID:23381221, PMID:23856246, PMID:23933261, PMID:24135919, PMID:24279929, PMID:24670534, PMID:25120651, PMID:25485619, PMID:25714623, PMID:25877200, PMID:25984343, PMID:26589293, PMID:27377824, PMID:27397505, PMID:27602502, PMID:27807467, PMID:28196595, PMID:29444439, PMID:29681454, PMID:29718670, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31733513, PMID:31803961, PMID:31978347, PMID:35839778, PMID:38861359

Comments: Karyotypic information: Has lost chromosome Y (PubMed=25714623)., Population: African American., Part of: NCI-7 clinical proteomics reference material cell line panel., Part of: NCI-60 cancer cell line panel., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H23

Synonyms: NCI.H23, NCI H23, H-23, H23, NCIH23

Cross References: BTO:BTO_0003238, CLO:CLO_0008071, EFO:EFO_0002286, AddexBio:C0016005/4861, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5800, BioGRID_ORCS_Cell_line:526, BioSample:SAMN03471316, BioSample:SAMN03471735, BioSample:SAMN10988149, cancercelllines:CVCL_1547, CCRID:3101HUMSCSP581, Cell_Model_Passport:SIDM00138, ChEMBL-Cells:CHEMBL3307750, ChEMBL-Targets:CHEMBL614997, CLS:305044, Cosmic:687818, Cosmic:722038, Cosmic:801587, Cosmic:844829, Cosmic:852004, Cosmic:875849, Cosmic:876142, Cosmic:877237, Cosmic:905942, Cosmic:910561, Cosmic:914948, Cosmic:917993, Cosmic:953983, Cosmic:961834, Cosmic:974292, Cosmic:1004697, Cosmic:1089217, Cosmic:1092619, Cosmic:1146906, Cosmic:1154591, Cosmic:1175864, Cosmic:1188590, Cosmic:1219060, Cosmic:1239881, Cosmic:1305347, Cosmic:1312332, Cosmic:1436010, Cosmic:1802313, Cosmic:1870271, Cosmic:1995567, Cosmic:1998461, Cosmic:2058647, Cosmic:2125183, Cosmic:2433751, Cosmic:2630416, Cosmic:2647631, Cosmic:2648436, Cosmic:2668310, Cosmic:2772151, Cosmic-CLP:905942, DepMap:ACH-000900, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:905942, GEO:GSM2106, GEO:GSM50214, GEO:GSM50277, GEO:GSM171868, GEO:GSM171869, GEO:GSM206487, GEO:GSM253310, GEO:GSM274790, GEO:GSM274820, GEO:GSM353232, GEO:GSM385519, GEO:GSM385530, GEO:GSM434335, GEO:GSM482108, GEO:GSM513961, GEO:GSM514346, GEO:GSM743453, GEO:GSM750803, GEO:GSM794267, GEO:GSM799341, GEO:GSM799404, GEO:GSM817066, GEO:GSM827478, GEO:GSM844643, GEO:GSM847075, GEO:GSM887421, GEO:GSM888500, GEO:GSM1153412, GEO:GSM1178456, GEO:GSM1178457, GEO:GSM1181268, GEO:GSM1181312, GEO:GSM1374733, GEO:GSM1374734, GEO:GSM1374735, GEO:GSM1670229, GEO:GSM2124674, IARC_TP53:256, IGRhCellID:NCIH23, KCLB:90023, LiGeA:CCLE_892, LINCS_LDP:LCL-1619, NCI-DTP:NCI-H23, PharmacoDB:NCIH23_1085_2019, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_1547, PubChem_Cell_line:CVCL_1547, SKY/M-FISH/CGH:2796, Wikidata:Q54907958

ID: CVCL_1547

Record Creation Time: 20220427T220839+0000

Record Last Update: 20260829T234742+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H23.

No alerts have been found for NCI-H23.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 370 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Chuikov S, et al. (2026) E2A selectively regulates TGF-?-induced apoptosis in KRAS-mutant non-small cell lung cancer. Molecular oncology, 20(7), 1877.

Li J, et al. (2026) Lactylation Enhances the Activity of Lactate Dehydrogenase A and Promotes the Chemoresistance to Cisplatin Through Facilitating DNA Nonhomologous End Junction in Lung Adenocarcinoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(3), e10733.

He D, et al. (2026) Study of the blood-brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases. Journal of the National Cancer Center, 6(3), 286.

Watlington WK, et al. (2026) Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. Molecular oncology.

Liu Y, et al. (2026) Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. Oncogene, 45(31), 3244.

Li Y, et al. (2026) Mitigating tumor heterogeneity in lung Cancer: A dual-targeted NIR-II imaging strategy for accurate tumor localization and intraoperative navigation. Cancer letters, 640, 218241.

Calderon-Aparicio A, et al. (2026) S6K1 Modulates STAT3 Activation to Promote Resistance to Radiotherapy in Lung Cancer. International journal of molecular sciences, 27(4).

Ge Y, et al. (2026) MTFR2 promotes VDAC1 oligomerization to reprogram BCAA metabolism in tumor cells to polarize TAMs in LUAD. Cell death & disease.

Meoni P, et al. (2026) Identification and Nonclinical Characterization of SAR444200, a Novel Anti-GPC3 NANOBODY T-cell Engager, for the Treatment of GPC3+ Solid Tumors. Molecular cancer therapeutics, 25(3), 361.

Shang X, et al. (2026) Dual PD-1/IL-2R? targeting restores CD8+ T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC. Cell reports. Medicine, 7(3), 102633.

Chen WT, et al. (2026) Functional genomic analysis reveals HAVCR1 as the key regulator of 5q33.3 locus linked to hyperlipidemia. HGG advances, 7(3), 100630.

Lang PA, et al. (2025) Optimized arenaviruses with tumor-tropic mutations promote safe anti-tumor efficacy via sustainable immune modulatory properties. Cell reports. Medicine, 6(10), 102411.

Negrao MV, et al. (2025) Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(6), 1069.

Lu S, et al. (2025) Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models. Molecular cancer therapeutics, 24(6), 920.

Daley BR, et al. (2025) SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma. Cancer research, 85(1), 118.

Park VS, et al. (2025) Lipid Composition Alters Ferroptosis Sensitivity. Cancer research, 85(22), 4380.

Srivastava PP, et al. (2025) Epigenetic co-regulator HCF-1 promotes lung cancer via O-GlcNAcylation-dependent pathways. Molecular therapy. Oncology, 33(4), 201046.

Jameson NM, et al. (2025) The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models. Cancer research communications, 5(2), 240.

Aggarwal RK, et al. (2025) Smoking-Associated Carcinogen-Induced Inflammation Promotes Lung Carcinogenesis via IRAK4 Activation. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(4), 746.

McCabe M, et al. (2025) Small molecule disruption of RAR?/NCoR1 interaction inhibits chaperone-mediated autophagy in cancer. EMBO molecular medicine, 17(7), 1716.